nach oben

Die Urologie

Erschienen in:

01.07.2009 | Leitthema

Immunmodulatorische Therapieansätze beim Prostatakarzinom

verfasst von: M.A. Reiter, J. Pfitzenmaier, M. Hohenfellner, PD Dr. A. Haferkamp

Erschienen in: Die Urologie | Ausgabe 7/2009

Einloggen, um Zugang zu erhalten

Zusammenfassung

Während der letzten 10 Jahre wurden verschiedene Ansätze zur Immuntherapie beim Prostatakarzinom untersucht. Dazu gehören unspezifische sowie spezifische immunstimulierende bzw. immunmodulierende Therapien. Bei der unspezifischen Immuntherapie des Prostatakarzinoms werden humorale und zelluläre Reaktionsmechanismen des Immunsystems antigenunspezifisch moduliert oder stimuliert. Ziel ist die Auslösung einer Entzündungsreaktion oder eines anderen bereits bestehenden Abwehrmechanismus zur Bekämpfung des Malignoms. Die Mediatoren und Effektorzellen dieser unspezifischen Immunantwort sind humorale Faktoren wie Zytokine, Komplement und Akutphaseproteine sowie zelluläre Komponenten des Immunsystems, wie Neutrophile, Makrophagen/Monozyten, Mastzellen und Natural-Killer-Zellen.

Im Gegensatz dazu ist es das Ziel der spezifischen Immuntherapie, zelluläre und humorale Immuneffektormechanismen zur zielgerichteten Erkennung und Zerstörung von Tumorzellen zu aktivieren. Die erfolgversprechendsten Ansätze der spezifischen Immuntherapie sind dabei Vakzinierungsstrategien mit Generierung einer antitumoralen T-Zell-Antwort und die Verabreichung von Antikörpern.

In Rahmen einer PubMed-basierten Literaturrecherche wurden Publikationen zur immunmodulatorischen Therapie des Prostatakarzinoms identifiziert. Der vorliegende Artikel fokussiert auf die zum Zeitpunkt der Publikation vorliegenden klinischen Studien zu immunmodulatorischen Therapieoptionen beim Prostatakarzinom und stellt deren bisherige Ergebnisse dar.

Ferlay J, Autier P, Boniol M et al (2007) Estimates of the cancer incidence and mortality in Europe in 2006. Ann Oncol 18(3): 581–592PubMedCrossRef

Jemal A, Siegel R, Ward E et al (2008) Cancer statistics. CA cancer J Clin 58(2): 71–96PubMedCrossRef

Pound CR, Partin AW, Eisenberger MA et al (1999) Natural history of progression after PSA elevation following radical prostatectomy. JAMA 281(17): 1591–1597PubMedCrossRef

Maximum androgen blockade in advanced prostate cancer (1995) an overview of 22 randomised trials with 3283 deaths in 5710 patients. Prostate Cancer Trialists Collaborative Group. Lancet 346(8970): 265–269

Petrylak DP, Tangen CM, Hussain MH et al (2004) Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 351(15): 1513–1520PubMedCrossRef

Tannock IF, de Wit R, Berry WR et al (2004) Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 351(15): 1502–1512PubMedCrossRef

Pollard M, Luckert PH (1993) The anti-metastatic effect of intravenously-inoculated BCG on prostate tumor cells. Anticancer Res 13(3): 705–708PubMed

Pollard M, Luckert PH (1994) The antimetastatic effect of IV-inoculated BCG on adenocarcinomas in the prostate-seminal vesicle complex of L-W rats. Anticancer Res 14(3A): 901–903PubMed

Guinan P, Toronchi E, Shaw M et al (1982) Bacillus calmette-guerin (BCG) adjuvant therapy in stage D prostate cancer. Urology 20(4): 401–403PubMedCrossRef

10.

Guinan PD, John T, Nagale V, Ablin RJ (1978) BCG adjuvant immunotherapy in carcinoma of the prostate: an interim report. Allergol Immunopathol (Madr) 6(4): 293–296

11.

Robinson MR, Rigby CC, Pugh RC, Dumonde DC (1977) Adjuvant immunotherapy with B.C.G. in carcinoma of the prostate. Br J Urol 49(3): 221–226PubMedCrossRef

12.

Robinson MR, Rigby CC, Pugh RC, Dumonde DC (1978) Prostate carcinoma: intratumor BCG immunotherapy. J Natl Cancer Inst Monogr 49: 351–353

13.

Hrouda D, Souberbielle BE, Kayaga J et al (1998) Mycobacterium vaccae (SRL172): a potential immunological adjuvant evaluated in rat prostate cancer. Br J Urol 82(6): 870–876PubMed

14.

Hrouda D, Baban B, Dunsmuir WD et al (1998) Immunotherapy of advanced prostate cancer: a phase I/II trial using Mycobacterium vaccae (SRL172). Br J Urol 82(4): 568–573PubMed

15.

Krejci KG, Markiewicz MA, Kwon ED (2004) Immunotherapy for urological malignancies. J Urol 171(2 Pt 1): 870–876PubMedCrossRef

16.

Heinzer H, Huland E, Huland H (2001) Systemic chemotherapy and chemoimmunotherapy for metastatic renal cell cancer. World J Urol 19(2): 111–119PubMedCrossRef

17.

Hautmann SH, Huland E, Huland H (1999) Local intratumor immunotherapy of prostate cancer with interleukin-2 reduces tumor growth. Anticancer Res 19(4A): 2661–2663PubMed

18.

Kocheril SV, Grignon DJ, Wang CY et al (1999) Responsiveness of human prostate carcinoma bone tumors to interleukin-2 therapy in a mouse xenograft tumor model. Cancer Detect Prev 23(5): 408–416PubMedCrossRef

19.

Dieli F, Vermijlen D, Fulfaro F et al (2007) Targeting human gamma delta T cells with zoledronate and interleukin-2 for immunotherapy of hormone-refractory prostate cancer. Cancer Res 67(15): 7450–7457PubMedCrossRef

20.

Maffezzini M, Simonato A, Fortis C (1996) Salvage immunotherapy with subcutaneous recombinant interleukin 2 (rIL-2) and alpha-interferon (A-IFN) for stage D3 prostate carcinoma failing second-line hormonal treatment. Prostate 28(5): 282–286PubMedCrossRef

21.

Dranoff G, Jaffee E, Lazenby A et al (1993) Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity. Proc Natl Acad Sci U S A 90(8): 3539–3543PubMedCrossRef

22.

Dreicer R, See WA, Klein EA (2001) Phase II trial of GM-CSF in advanced prostate cancer. Invest New Drugs 19(3): 261–265PubMedCrossRef

23.

Small EJ, Reese DM, Um B et al (1999) Therapy of advanced prostate cancer with granulocyte macrophage colony-stimulating factor. Clin Cancer Res 5(7): 1738–1744PubMed

24.

Rini BI, Weinberg V, Bok R, Small EJ (2003) Prostate-specific antigen kinetics as a measure of the biologic effect of granulocyte-macrophage colony-stimulating factor in patients with serologic progression of prostate cancer. J Clin Oncol 21(1): 99–105PubMedCrossRef

25.

Rini BI, Fong L, Weinberg V et al (2006) Clinical and immunological characteristics of patients with serologic progression of prostate cancer achieving long-term disease control with granulocyte-macrophage colony-stimulating factor. J Urol 175(6): 2087–2091PubMedCrossRef

26.

Ryan CJ, Weinberg V, Rosenberg J et al (2007) Phase II study of ketoconazole plus granulocyte-macrophage colony-stimulating factor for prostate cancer: effect of extent of disease on outcome. J Urol 178(6): 2372–2376PubMedCrossRef

27.

Dreicer R, Klein EA, Elson P et al (2005) Phase II trial of GM-CSF + thalidomide in patients with androgen-independent metastatic prostate cancer. Urol Oncol 23(2): 82–86PubMed

28.

Kramer G, Steiner GE, Sokol P et al (2001) Local intratumoral tumor necrosis factor-alpha and systemic IFN-alpha 2b in patients with locally advanced prostate cancer. J Interferon Cytokine Res 21(7): 475–484PubMedCrossRef

29.

Kiessling A, Fussel S, Wehner R et al (2008) Advances in specific immunotherapy for prostate cancer. Eur Urol 53(4): 694–708PubMedCrossRef

30.

Noguchi M, Itoh K, Yao A et al (2005) Immunological evaluation of individualized peptide vaccination with a low dose of estramustine for HLA-A24+ HRPC patients. Prostate 63(1): 1–12PubMedCrossRef

31.

Gates JD, Carmichael MG, Benavides LC et al (2009) Longterm followup assessment of a HER2/neu peptide (E75) vaccine for prevention of recurrence in high-risk prostate cancer patients. J Am Coll Surg 208(2): 193–201PubMedCrossRef

32.

Eder JP, Kantoff PW, Roper K et al (2000) A phase I trial of a recombinant vaccinia virus expressing prostate-specific antigen in advanced prostate cancer. Clin Cancer Res 6(5): 1632–1638PubMed

33.

Gulley J, Chen AP, Dahut W et al (2002) Phase I study of a vaccine using recombinant vaccinia virus expressing PSA (rV-PSA) in patients with metastatic androgen-independent prostate cancer. Prostate 53(2): 109–117PubMedCrossRef

34.

Kaufman HL, Wang W, Manola J et al (2004) Phase II randomized study of vaccine treatment of advanced prostate cancer (E7897): a trial of the Eastern Cooperative Oncology Group. J Clin Oncol 22(11): 2122–2132PubMedCrossRef

35.

Arlen PM, Gulley JL, Parker C et al (2006) A randomized phase II study of concurrent docetaxel plus vaccine versus vaccine alone in metastatic androgen-independent prostate cancer. Clin Cancer Res 12(4): 1260–1269PubMedCrossRef

36.

Amato RJ, Drury N, Naylor S et al (2008) Vaccination of prostate cancer patients with modified vaccinia ankara delivering the tumor antigen 5T4 (TroVax): a phase 2 trial. J Immunother 31(6): 577–585PubMedCrossRef

37.

Madan RA, Gulley JL, Schlom J et al (2008) Analysis of overall survival in patients with nonmetastatic castration-resistant prostate cancer treated with vaccine, nilutamide and combination therapy. Clin Cancer Res 14(14): 4526–4531PubMedCrossRef

38.

Pavlenko M, Roos AK, Lundqvist A et al (2004) A phase I trial of DNA vaccination with a plasmid expressing prostate-specific antigen in patients with hormone-refractory prostate cancer. Br J Cancer 91(4): 688–694PubMed

39.

Simons JW, Carducci MA, Mikhak B et al (2006) Phase I/II trial of an allogeneic cellular immunotherapy in hormone-naive prostate cancer. Clin Cancer Res 12(11 Pt 1): 3394–3401PubMedCrossRef

40.

Urba WJ, Nemunaitis J, Marshall F et al (2008) Treatment of biochemical recurrence of prostate cancer with granulocyte-macrophage colony-stimulating factor secreting, allogeneic, cellular immunotherapy. J Urol 180(5): 2011–2017PubMedCrossRef

41.

Small EJ, Sacks N, Nemunaitis J et al (2007) Granulocyte macrophage colony-stimulating factor--secreting allogeneic cellular immunotherapy for hormone-refractory prostate cancer. Clin Cancer Res 13(13): 3883–3891PubMedCrossRef

42.

Higano CS, Corman JM, Smith DC et al (2008) Phase 1/2 dose-escalation study of a GM-CSF-secreting, allogeneic, cellular immunotherapy for metastatic hormone-refractory prostate cancer. Cancer 113(5): 975–984PubMedCrossRef

43.

Steinman RM (2003) Some interfaces of dendritic cell biology. Apmis 111(7–8): 675–697

44.

Hsu FJ, Benike C, Fagnoni F et al (1996) Vaccination of patients with B-cell lymphoma using autologous antigen-pulsed dendritic cells. Nat Med 2(1): 52–58PubMedCrossRef

45.

Nestle FO, Alijagic S, Gilliet M et al (1998) Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells. Nat Med 4(3): 328–332PubMedCrossRef

46.

Murphy G, Tjoa B, Ragde H et al (1996) Phase I clinical trial: T-cell therapy for prostate cancer using autologous dendritic cells pulsed with HLA-A0201-specific peptides from prostate-specific membrane antigen. Prostate 29(6): 371–380PubMedCrossRef

47.

Tjoa BA, Erickson SJ, Bowes VA et al (1997) Follow-up evaluation of prostate cancer patients infused with autologous dendritic cells pulsed with PSMA peptides. Prostate 32(4): 272–278PubMedCrossRef

48.

Tjoa BA, Simmons SJ, Bowes VA et al (1998) Evaluation of phase I/II clinical trials in prostate cancer with dendritic cells and PSMA peptides. Prostate 36(1): 39–44PubMedCrossRef

49.

Waeckerle-Men Y, Uetz-von Allmen E, Fopp M et al (2006) Dendritic cell-based multi-epitope immunotherapy of hormone-refractory prostate carcinoma. Cancer Immunol Immunother 55(12): 1524–1533PubMedCrossRef

50.

Barrou B, Benoit G, Ouldkaci M et al (2004) Vaccination of prostatectomized prostate cancer patients in biochemical relapse, with autologous dendritic cells pulsed with recombinant human PSA. Cancer Immunol Immunother 53(5): 453–460PubMedCrossRef

51.

Heiser A, Coleman D, Dannull J et al (2002) Autologous dendritic cells transfected with prostate-specific antigen RNA stimulate CTL responses against metastatic prostate tumors. J Clin Invest 109(3): 409–417PubMed

52.

Su Z, Dannull J, Yang BK et al (2005) Telomerase mRNA-transfected dendritic cells stimulate antigen-specific CD8+ and CD4+ T cell responses in patients with metastatic prostate cancer. J Immunol 174(6): 3798–3807PubMed

53.

Small EJ, Fratesi P, Reese DM et al (2000) Immunotherapy of hormone-refractory prostate cancer with antigen-loaded dendritic cells. J Clin Oncol 18(23): 3894–3903PubMed

54.

Small EJ, Schellhammer PF, Higano CS et al (2006) Placebo-controlled phase III trial of immunologic therapy with sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer. J Clin Oncol 24(19): 3089–3094PubMedCrossRef

55.

Milowsky MI, Nanus DM, Kostakoglu L et al (2004) Phase I trial of yttrium-90-labeled anti-prostate-specific membrane antigen monoclonal antibody J591 for androgen-independent prostate cancer. J Clin Oncol 22(13): 2522–2531PubMedCrossRef

56.

Bander NH, Milowsky MI, Nanus DM et al (2005) Phase I trial of 177lutetium-labeled J591, a monoclonal antibody to prostate-specific membrane antigen, in patients with androgen-independent prostate cancer. J Clin Oncol 23(21): 4591–4601PubMedCrossRef

57.

Galsky MD, Eisenberger M, Moore-Cooper S et al (2008) Phase I trial of the prostate-specific membrane antigen-directed immunoconjugate MLN2704 in patients with progressive metastatic castration-resistant prostate cancer. J Clin Oncol 26(13): 2147–2154PubMedCrossRef

58.

Lara PN Jr, Chee KG, Longmate J et al (2004) Trastuzumab plus docetaxel in HER-2/neu-positive prostate carcinoma: final results from the California Cancer Consortium Screening and Phase II Trial. Cancer 100(10): 2125–2131PubMedCrossRef

59.

Slovin SF, Scher HI, Divgi CR et al (1998) Interferon-gamma and monoclonal antibody 131I-labeled CC49: outcomes in patients with androgen-independent prostate cancer. Clin Cancer Res 4(3): 643–651PubMed

60.

Di Lorenzo G, Figg WD, Fossa SD et al (2008) Combination of bevacizumab and docetaxel in docetaxel-pretreated hormone-refractory prostate cancer: a phase 2 study. Eur Urol 54(5): 1089–1094CrossRef

61.

Fong L, Kwek SS, O’Brien S et al (2009) Potentiating endogenous antitumor immunity to prostate cancer through combination immunotherapy with CTLA4 blockade and GM-CSF. Cancer Res 69(2): 609–615PubMedCrossRef

62.

Emerson L, Morales A (2009) Intralesional recombinant alpha-interferon localised prostate cancer: a pilot study with follow-up of 10 years. BJU (epub ahead)

Titel: Immunmodulatorische Therapieansätze beim Prostatakarzinom
verfasst von: M.A. Reiter
J. Pfitzenmaier
M. Hohenfellner
PD Dr. A. Haferkamp
Publikationsdatum: 01.07.2009
Verlag: Springer-Verlag
Erschienen in: Die Urologie / Ausgabe 7/2009
Print ISSN: 2731-7064
Elektronische ISSN: 2731-7072
DOI: https://doi.org/10.1007/s00120-009-1984-6

Neu im Fachgebiet Urologie

22.04.2024 | Prostatakarzinom | Nachrichten

Update Urologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Immunmodulatorische Therapieansätze beim Prostatakarzinom

Zusammenfassung

Neu im Fachgebiet Urologie

Stufenschema weist Prostatakarzinom zuverlässig nach

Harnwegsinfektprophylaxe: Es geht auch ohne Antibiotika

Varikozelen bei Jugendlichen: Das Für und Wider der Operation

Ureterstriktur: Innovative OP-Technik bewährt sich

Update Urologie

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Zusammenfassung

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 7/2009

Berufspolitik BDU, Heft 7/2009

Hoch intensiver fokussierter transrektaler Ultraschall (rHIFU) zur lokalen Therapie des Prostatakarzinoms

G-DRG-Systemanpassung 2009

URO-Telegramm und Newsletter, Heft 7/2009

Urologie-Updateseminar UroUpdate

Der Stellenwert der Galvanotherapie beim lokal begrenzten Prostatakarzinom

Neu im Fachgebiet Urologie

Stufenschema weist Prostatakarzinom zuverlässig nach

Harnwegsinfektprophylaxe: Es geht auch ohne Antibiotika

Varikozelen bei Jugendlichen: Das Für und Wider der Operation

Ureterstriktur: Innovative OP-Technik bewährt sich

Update Urologie